A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PMID: 24068931
Novel prime-boost vaccine strategies against HIV-1. PMID: 31271322
Targeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus Macaques. PMID: 27077384
Trimeric HIV-1 gp140 fused with APRIL, BAFF, and CD40L on the mucosal gp140-specific antibody responses in mice. PMID: 32014267
HIV-1 envelope protein gp140 binding studies to human brain microvascular endothelial cells. PMID: 17888880
One-step sequence and structure-guided optimization of HIV-1 envelope gp140. PMID: 33688632
Retraction: Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vector. PMID: 33315934
HIV-1 gp140 epitope recognition is influenced by immunoglobulin DH gene segment sequence. PMID: 26687685
Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures. PMID: 21709254
Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). PMID: 30047376
Broad HIV-1 neutralizing antibody response induced by heterologous gp140/gp145 DNA prime-vaccinia boost immunization. PMID: 22561314
Characterization of native-like HIV-1 gp140 glycoprotein expressed in insect cells. PMID: 30737044
Purified, proteolytically mature HIV type 1 SOSIP gp140 envelope trimers. PMID: 17604546
IL-17A and IL-17F repair HIV-1 gp140 damaged Caco-2 cell barriers by upregulating tight junction genes. PMID: 30951887
HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine. PMID: 29021394
Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study. PMID: 33010242
New concepts in HIV-1 vaccine development. PMID: 27268856
Lessons from HIV-1 vaccine efficacy trials. PMID: 27537673
Characterization and Immunogenicity of HIV Envelope gp140 Zera® Tagged Antigens. PMID: 32328488
Neutralizing Antibody Responses following Long-Term Vaccination with HIV-1 Env gp140 in Guinea Pigs. PMID: 29643249
Antigenicity and immunogenicity of HIV-1 gp140 with different combinations of glycan mutation and V1/V2 region or V3 crown deletion. PMID: 31564450
Increased, Durable B-Cell and ADCC Responses Associated with T-Helper Cell Responses to HIV-1 Envelope in Macaques Vaccinated with gp140 Occluded at the CD4 Receptor Binding Site. PMID: 28701402
Uncleaved prefusion-optimized gp140 trimers derived from analysis of HIV-1 envelope metastability. PMID: 27349805
Characterization and immunogenicity of a novel mosaic M HIV-1 gp140 trimer. PMID: 24965452
Stable, uncleaved HIV-1 envelope glycoprotein gp140 forms a tightly folded trimer with a native-like structure. PMID: 25512514
HIV-1 Envelope Recognition by Polyreactive and Cross-Reactive Intestinal B Cells. PMID: 30970259
Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses. PMID: 28202751
HIV-gp140-Specific Antibodies Generated From Indian Long-Term Non-Progressors Mediate Potent ADCC Activity and Effectively Lyse Reactivated HIV Reservoir. PMID: 35309295
Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques. PMID: 28490585
Deglycosylation or partial removal of HIV-1 CN54 gp140 V1/V2 domain enhances env-specific T cells. PMID: 19500018
Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses. PMID: 21931643
Antibody responses to prime-boost vaccination with an HIV-1 gp145 envelope protein and chimpanzee adenovirus vectors expressing HIV-1 gp140. PMID: 27525550
Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies. PMID: 15665645
Single-Chain Soluble BG505.SOSIP gp140 Trimers as Structural and Antigenic Mimics of Mature Closed HIV-1 Env. PMID: 25740988
HIV-1 specific IgA detected in vaginal secretions of HIV uninfected women participating in a microbicide trial in Southern Africa are primarily directed toward gp120 and gp140 specificities. PMID: 25054205
Germline-targeting immunogens. PMID: 28133796
Comparison of multiple adjuvants on the stability and immunogenicity of a clade C HIV-1 gp140 trimer. PMID: 24556505
Enhanced immunogenicity of HIV-1 envelope gp140 proteins fused to APRIL. PMID: 25247707
Developability Assessment of Physicochemical Properties and Stability Profiles of HIV-1 BG505 SOSIP.664 and BG505 SOSIP.v4.1-GT1.1 gp140 Envelope Glycoprotein Trimers as Candidate Vaccine Antigens. PMID: 30776383
Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vector. PMID: 24098600
DNA adjuvant Amiloride conjunct long immunization interval promote higher antibody responses to HIV-1 gp41 and gp140 immunogens. PMID: 33041100
Immunogenicity testing of a novel engineered HIV-1 envelope gp140 DNA vaccine construct. PMID: 16848679
Vaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramide. PMID: 24920809
Comparative Analysis of the Glycosylation Profiles of Membrane-Anchored HIV-1 Envelope Glycoprotein Trimers and Soluble gp140. PMID: 26018173
Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization. PMID: 17540729
Performance evaluation of the Bio-Rad Geenius HIV 1/2 supplemental assay. PMID: 30594702
HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers. PMID: 26089353
Breadth of HIV-1 Env-specific antibody-dependent cellular cytotoxicity: relevance to global HIV vaccine design. PMID: 24937308
Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre Study. PMID: 27159166
Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs. PMID: 20053749
An HIV-1 Broadly Neutralizing Antibody from a Clade C-Infected Pediatric Elite Neutralizer Potently Neutralizes the Contemporaneous and Autologous Evolving Viruses. PMID: 30429339
Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans. PMID: 33859204
Selection of nanobodies with broad neutralizing potential against primary HIV-1 strains using soluble subtype C gp140 envelope trimers. PMID: 28827559
Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies. PMID: 17306322
CCL19 and CCL28 augment mucosal and systemic immune responses to HIV-1 gp140 by mobilizing responsive immunocytes into secondary lymph nodes and mucosal tissue. PMID: 23858028
Comparison of immunogenicity between codon optimized HIV-1 Thailand subtype B gp140 and gp145 vaccines. PMID: 17350736
Development of a synthetic nanoparticle vaccine presenting the HIV-1 envelope glycoprotein. PMID: 35882111
Computational Evaluation of HIV-1 gp120 Conformations of Soluble Trimeric gp140 Structures as Targets for de Novo Docking of First- and Second-Generation Small-Molecule CD4 Mimics. PMID: 27602436
V2 hotspot optimized MVA vaccine expressing stabilized HIV-1 Clade C envelope Gp140 delays acquisition of heterologous Clade C Tier 2 challenges in Mamu-A*01 negative Rhesus Macaques. PMID: 35935987
HIV-1 subtype C transmitted founders modulate dendritic cell inflammatory responses. PMID: 32615983
Differential binding of the HIV-1 envelope to phosphatidylserine receptors. PMID: 28622976
Associating HIV-1 envelope glycoprotein structures with states on the virus observed by smFRET. PMID: 30971821
Human monoclonal antibodies to HIV-1 gp140 from mice bearing YAC-based human immunoglobulin transloci. PMID: 21810921
Boosting of HIV-1 neutralizing antibody responses by a distally related retroviral envelope protein. PMID: 24829409
HIV-1 vaccine design through minimizing envelope metastability. PMID: 30474059
Intradermal HIV-1 DNA Immunization Using Needle-Free Zetajet Injection Followed by HIV-Modified Vaccinia Virus Ankara Vaccination Is Safe and Immunogenic in Mozambican Young Adults: A Phase I Randomized Controlled Trial. PMID: 28969431
Characterization of immune responses elicited in mice by intranasal co-immunization with HIV-1 Tat, gp140 DeltaV2Env and/or SIV Gag proteins and the nontoxicogenic heat-labile Escherichia coli enterotoxin. PMID: 18243435
Generation of HIV-1 Virus-Like Particles expressing different HIV-1 glycoproteins. PMID: 21596074
Gp120 on HIV-1 Virions Lacks O-Linked Carbohydrate. PMID: 25915761
Targeting human langerin promotes HIV-1 specific humoral immune responses. PMID: 34324611
HIV-1 vaccines based on replication-competent Tiantan vaccinia protected Chinese rhesus macaques from simian HIV infection. PMID: 25849828
Effect of trimerization motifs on quaternary structure, antigenicity, and immunogenicity of a noncleavable HIV-1 gp140 envelope glycoprotein. PMID: 19815247
Immunization with recombinant HLA classes I and II, HIV-1 gp140, and SIV p27 elicits protection against heterologous SHIV infection in rhesus macaques. PMID: 21490092
Rapid Boosting of HIV-1 Neutralizing Antibody Responses in Humans Following a Prolonged Immunologic Rest Period. PMID: 30615119
Comparison of neutralizing antibody responses elicited from highly diverse polyvalent heterotrimeric HIV-1 gp140 cocktail immunogens versus a monovalent counterpart in rhesus macaques. PMID: 25490553
Anti-HIV-1 antibody-dependent cellular cytotoxicity mediated by hyperimmune bovine colostrum IgG. PMID: 22730083
Directed evolution of a yeast-displayed HIV-1 SOSIP gp140 spike protein toward improved expression and affinity for conformational antibodies. PMID: 25688555
HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120. PMID: 22773820
A Systematic Approach to HIV-1 Vaccine Immunogen Selection. PMID: 32056466
For research use only. Not for human or drug use.
